Brief: Immunocore Converts Phase 2/3 TEBE-AM Clinical Trial Into Registrational Phase 3 Trial

Immunocore Holdings

29/05/2024 12:12

May 29 (Reuters) - Immunocore Holdings PLC  IMCR.O :
    * IMMUNOCORE CONVERTS PHASE 2/3 TEBE-AM CLINICAL TRIAL INTO
REGISTRATIONAL PHASE 3 TRIAL EVALUATING KIMMTRAK FOR PREVIOUSLY
TREATED ADVANCED CUTANEOUS MELANOMA
    * IMMUNOCORE  - EXPECTED TO ACCELERATE TIME TO FINAL PHASE 3
OVERALL SURVIVAL ANALYSIS

Source text for Eikon:  ID:nGNX1xDxJx 
Further company coverage:  IMCR.O 

 ((Reuters.Briefs@thomsonreuters.com;))